help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on December 13, 2007
Endocrinology, doi:10.1210/en.2007-0542
A more recent version of this article appeared on March 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
149/3/1235    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elston, M. S
Right arrow Articles by McDonald, K. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elston, M. S
Right arrow Articles by McDonald, K. L

Submitted on October 15, 2007
Accepted on December 3, 2007

Wnt pathway inhibitors are strongly down-regulated in pituitary tumors

Marianne S Elston*, Anthony J Gill, John V Conaglen, Adele Clarkson, Janet M Shaw, Andrew JJ Law, Raymond J Cook, Nicholas S Little, Roderick J Clifton-Bligh, Bruce G Robinson, and Kerrie L McDonald

Cancer Genetics Unit, Kolling Institute of Medical Research, Sydney, Australia; Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, and University of Sydney, Sydney Australia; Department of Endocrinology, Waikato Hospital, Waikato, New Zealand; Department of Neurosurgery, Auckland City Hospital, Auckland, New Zealand, Department of Neurosurgery, Royal North Shore and North Shore Private Hospitals, Sydney, Australia, and Faculty of Medicine, University of Sydney, Sydney, Australia

* To whom correspondence should be addressed. E-mail: marianne{at}med.usyd.edu.au.

The etiology of sporadic pituitary tumors is currently unknown. The Wnt pathways have been implicated in the pathogenesis of a variety of human tumors but the role of these pathways in pituitary tumors is unclear. Microarray analysis using the Affymetrix HG U133 plus 2.0 GeneChips identified four secreted frizzled-related protein (sFRP) family members of Wnt pathway inhibitors that were differentially expressed in both nonfunctioning and clinically functioning pituitary tumors (n=20) compared with normal pituitary controls (n=3). Reduced tumor expression of Wnt inhibitory factor-1 (WIF1), sFRP2 and sFRP4 mRNA was confirmed by real-time quantitative RT-PCR (p <0.001, p=0.002 and 0.013 respectively) in all pituitary subtypes. Hypermethylation of the WIF1 promoter was present in 88% of the pituitary tumors (n=41). Seventy-six percent of pituitary tumors demonstrated absent or weak cytoplasmic WIF1 staining by immunohistochemistry (n=41), although preserved staining was seen in some functioning tumors, with strong staining in 92% of normal pituitary controls (n= 13). The Wnt pathway target gene, cyclin D1 was found to be up-regulated specifically in the nonfunctioning pituitary tumors compared with controls at both mRNA and protein level, supportive of activation of the Wnt-beta-catenin pathway. Nuclear accumulation of beta-catenin, however, was not observed in any pituitary tumors (n=70). By transfecting GH3 cells with WIF1, decreased cell proliferation and colony formation was observed compared with empty vector controls. In conclusion, our data suggests that WIF1 may be a tumor suppressor, specifically in non-functioning pituitary tumors, and that the Wnt pathways are important in pituitary tumorigenesis.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society